ClinicalTrials.Veeva

Menu

Mg OSTEOCRETE Post-Treatment Outcomes

S

Santiago Lozano-Calderon

Status

Not yet enrolling

Conditions

Aseptic Loosening of Orthopaedic Hardware
Trauma
Cancer of Bone

Treatments

Device: Mg OSTEOCRETE as a bone void filler

Study type

Observational

Funder types

Other

Identifiers

NCT06720142
2024P003397

Details and patient eligibility

About

Mg OSTEOCRETE is a bone substitute used to fill a defect in bone caused by excision of a tumor, orthopaedic hardware that has become loosened, or a trauma-related condition. The aim of this study is to determine the amount of time it takes for bone to heal after treatment with Mg OSTEOCRETE, and to better understand the efficacy of this treatment through clinical and patient-reported outcomes.

Full description

Bone voids in the skeletal system can result from trauma, infection, surgery, or oncologic disease. If these voids are not treated, they may lead to issues such as pathological fractures, treatment or hardware failure, and recurrence of disease. Various methods exist for addressing bone voids, primarily through the use of grafting materials. Autograft-bone harvested from another part of the same patient and transplanted into the void-is considered the "gold standard" because they fulfill all three criteria of the "ideal" void filler: they are osteoconductive, osteoinductive, and osteogenic. However, their use can be limited by availability and potential donor site complications, with up to 39% of patients reporting pain at the donor site.

Due to concerns with traditional bone grafting methods, there is growing interest in alternative options. While allografts carry a risk of disease transmission and xenografts are prone to immune rejection, synthetic bone graft substitutes offer a promising alternative. These substitutes, made from materials like calcium sulfate or calcium phosphate, address many issues associated with autografts and allografts. With improved understanding of their performance post-implantation, ongoing advancements are being made. This Clinical Investigation Plan outlines an observational study to evaluate clinical and radiographic outcomes with a particular synthetic bone graft substitute (Mg OSTEOCRETE™; Alliant Biotech, LLC; Grand Rapids, MI).

Mg OSTEOCRETE™ is a moldable/injectable magnesium-based void filler that provides stability while also increasing cell proliferation. Use of Mg OSTEOCRETE™ has been shown to advance the rate of mineralization with a result of enhanced bone regeneration for multiple types of orthopedic applications.

Enrollment

10 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years of age and older on the day of surgery

  • has received or will receive Mg OSTEOCRETE as a component of their treatment at this institution in accordance with Instructions for Use for the implanted product

  • Mg OSTEOCRETE is indicated for one of the following reasons:

    1. as a bone void filler following bone tumor resection, or;
    2. as an augment for defects causing aseptic loosening of orthopaedic implants, or;
    3. to help substitute bone for trauma-related conditions

Exclusion criteria

  • any contraindication as per Instructions for Use for Mg OSTEOCRETE

Trial design

10 participants in 3 patient groups

Bone void following bone tumor resection
Description:
Patients are being targeted because they have already agreed to receive OSTEOCRETE as part of standard clinical care. They will complete surveys, blood draws to test for magnesium levels, and low-dose CT scans at various post-operative timepoints.
Treatment:
Device: Mg OSTEOCRETE as a bone void filler
Device: Mg OSTEOCRETE as a bone void filler
Device: Mg OSTEOCRETE as a bone void filler
Bone defect caused by aseptic loosening of orthopaedic implants
Description:
Patients are being targeted because they have already agreed to receive OSTEOCRETE as part of standard clinical care. They will complete surveys, blood draws to test for magnesium levels, and low-dose CT scans at various post-operative timepoints.
Treatment:
Device: Mg OSTEOCRETE as a bone void filler
Device: Mg OSTEOCRETE as a bone void filler
Device: Mg OSTEOCRETE as a bone void filler
Bone defect caused by trauma-related condition
Description:
Patients are being targeted because they have already agreed to receive OSTEOCRETE as part of standard clinical care. They will complete surveys, blood draws to test for magnesium levels, and low-dose CT scans at various post-operative timepoints.
Treatment:
Device: Mg OSTEOCRETE as a bone void filler
Device: Mg OSTEOCRETE as a bone void filler
Device: Mg OSTEOCRETE as a bone void filler

Trial contacts and locations

1

Loading...

Central trial contact

Lucy L Hederick, BA; Santiago A Lozano-Calderon, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems